Clinical trial · Observational
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
NCT07041827CI-TRIAL-00091477CLARITYcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and their influence on survival.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiomyopathies | — | UNRESOLVED | — |
| Cardiotoxicity | — | UNRESOLVED | — |
| Cardiovascular Diseases | — | UNRESOLVED | — |
| DLBCL | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
| Heart Failure | — | UNRESOLVED | — |
| Late Effect | — | UNRESOLVED | — |
| Metabolic Syndrome | — | UNRESOLVED | — |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiovascular assessment | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Survivors
- description
- Over the past years, a Dutch multicentre hospital-based patient cohort of 5-year non-Hodgkin lymphoma survivors has been established. Survivors will be invited for the current study by their treating physician through the BETER survivorship clinics, or when patients have been dismissed from clinical follow-up, by their former treating physician (or head of the medical department, if the treating physician is retired) within each BETER clinic.
- interventionNames
- Diagnostic Test: Cardiovascular assessment
- label
- Siblings
- description
- As there are no patients who are unexposed to potential cardiotoxic treatment in the BETER cohort we will request every participating NHL survivor to approach one of their siblings, more specifically the sibling who is closest in birthdate to the birthdate of the survivor, for participation in the study.
- interventionNames
- Diagnostic Test: Cardiovascular assessment
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria (survivors): * 5-15 year survivors from the patient cohort with (mediastinal) large B-cell non-Hodgkin lymphoma (ICD-code 9679) or diffuse large B-cell non-Hodgkin lymphoma (ICD-code 9684), treated with R-CHOP: * 200 survivors treated between five to ten years ago (2007-2012) * 150 survivors treated between ten to fifteen years ago (2002-2007) * Treated in one of the following centers: AVL, Amsterdam UMC (location VUmc or AMC), LUMC, EMC, UMCU, UMCG, UMC Radboud. * Age at diagnosis 15 up to 60 years. * Age at the time of inclusion: younger than 75 years old. Exclusion criteria (survivors): * Use of immunosuppressant and/or prednisolone * HIV-infected individuals * Pregnant women * Mental disability or psychological condition potentially hampering compliance with the study protocol * Insufficient understanding of the Dutch language Inclusion criteria (siblings): 175 siblings of the above mentioned patients (maximum of 1 sibling per patient) with their date of birth closest to the birthdate of the survivor. Exclusion Criteria (siblings): * Use of immunosuppressant and/or prednisolone * HIV-infected individuals * Pregnant women * Mental disability or psychological condition potentially hampering compliance with the study protocol * Insufficient understanding of the Dutch language
References
Publications (0)
Data not yet available
No reference posted for this study.